Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T14:50:44.557Z.
Calculation as of: 2026-10-06T14:50:44.557Z.
Quote observation: 2026-10-06T14:50:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ad057aee5ab633aed0c7ef60ea3d5b85ea99b1ff07310db4f6411376a188a91d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$847.73M
Price/FCF Ratio
N/A
TTM Avg
12.01
3Y Avg
12.01
5Y Avg
12.01
Market Cap
$870.53M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alumis Inc. (ALMS) | $830.70M | N/A | N/A | N/A | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $838.16M | N/A | N/A | N/A | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $821.00M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $847.73M | N/A | 12.01 | 12.01 | 12.01 |
| Ardelyx, Inc. (ARDX)vs › | $809.02M | N/A | 8.01 | 8.93 | 8.93 |
| InMode Ltd. (INMD)vs › | $805.59M | 9.21 | 9.91 | 9.93 | 15.12 |
| Apnimed, Inc. (APMD)vs › | $807.90M | N/A | N/A | N/A | N/A |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $870.53M | N/A | N/A | N/A | N/A |
| AdaptHealth Corp. (AHCO)vs › | $784.35M | 8.03 | 7.03 | 12.33 | 28.28 |
| Gyre Therapeutics, Inc. (GYRE)vs › | $785.44M | N/A | 424.04 | 254.96 | 216.79 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
